http://www.fresenius.com en-us Wed, 11 Dec 2019 00:00:00 +0100 Wed, 11 Dec 2019 00:00:00 +0100 Wed, 11 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

]]>
Tue, 10 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Helios awards new innovation prize]]> Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

]]>
Wed, 13 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Fosaprepitant, an antiemetic, expands the company's large sterile injectable portfolio in oncology.

]]>
Tue, 12 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed completes main university hospital building in Lübeck]]> After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Lübeck. Following the opening in August of the new main building at the UKSH’s other location, in Kiel, the modernization of Germany’s second-largest university hospital is now largely complete. In addition to the new construction and the comprehensive renovation of the two university hospital locations, the project includes their technical management through 2044. With a total volume of €1.7 billion, the UKSH modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

]]>
Tue, 05 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed wins awards for spa and wellness facilities]]> VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2019” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Spa Villas, St. Martins Therme & Lodge, Therme Laa Hotel & Spa and la pura women’s health resort – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria.

]]>
Mon, 04 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Helios acquires medical diagnostics provider in Colombia ]]> Quirónsalud, Spain’s largest private hospital group and part of Fresenius Helios, has acquired CediMed, a leading medical diagnostics group in Colombia.

]]>
Tue, 29 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius confirms guidance after solid third quarter]]> Strong organic sales growth across all business segments - Growth investments proceeding according to plan - Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America - Fresenius Helios showing excellent organic sales growth across all regions - Fresenius Medical Care with record growth in home dialysis in North America

]]>
Fri, 25 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches new Heparin Sodium in prefilled syringe in the U.S.]]> A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

]]>
Wed, 23 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi expands plant in Brazil]]> Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

]]>
Mon, 07 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches Fulvestrant in prefilled syringes in the U.S.]]> Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

]]>
Wed, 18 Sep 2019 08:00:00 +0100 <![CDATA[Fresenius Helios develops system to measure patient safety]]> Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

]]>
Wed, 18 Sep 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi opens research and development center for biosimilars in Switzerland]]> Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

]]>
Tue, 17 Sep 2019 08:00:00 +0100 <![CDATA[Fresenius SE & Co. KGaA included in Dow Jones Sustainability Index]]> Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.

]]>
Mon, 16 Sep 2019 08:00:00 +0100 <![CDATA[2020 DRG inflator for German hospitals set at 3.66%]]> The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

]]>
Wed, 11 Sep 2019 08:00:00 +0100 <![CDATA[Fresenius Helios launches digital portal for patients]]> Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.

]]>
Tue, 03 Sep 2019 08:00:00 +0100 <![CDATA[Fresenius Helios acquires two hospitals in Colombia]]> Quirónsalud, Spain’s largest private hospital group and part of Fresenius Helios, has acquired Clínica Las Vegas and Clínica del Prado and further expanded its presence in the attractive private hospital market in Colombia.

]]>
Fri, 30 Aug 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S. ]]> Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

]]>
Tue, 20 Aug 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed completes main university hospital building in Kiel]]> After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

]]>
Mon, 05 Aug 2019 08:00:00 +0100 <![CDATA[Fresenius Helios expands preventive medicine offering]]> Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

]]>
Tue, 30 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius raises Group sales growth guidance after good second quarter ]]> Good organic sales growth across all business segments - Growth investments well on track - Fresenius Kabi successfully launched first biosimilar in Europe; continued excellent growth in Emerging Markets - Fresenius Helios showing strong organic sales growth in Germany and enters successfully Colombian hospital market - Fresenius Medical Care’s strategy reinforced by U.S. government’s plans for changes of kidney disease care

]]>